Clinical Trial Search

Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants

Primary: Change From Baseline in Overall Dry Skin Score (ODS) — -0.9; -1.2; -0.9 units on a scale

Primary: Change in Histology

Primary: Percentage of Subjects Who Correctly Answered a Knowledge Assessment Item Immediately Before and After an Educational Lecture — 52; 94; 19; 90 percentage of participants

Primary: SCORAD Change Score — 33.34 Change Score

Primary: Skin Healing Time — 13.75; 19; 40.5; 34 days — p=0.01

Primary: Psoriasis Area and Severity Index (PASI) Score — 3.9 score on a scale

Primary: Adherence - MEMs Cap — 21; 6; 15; 12 Participants

Primary: Change From Baseline in the Total Number of Papulopustular Lesions at Week 12 — -0.2 papule count — p=0.98

Primary: Photoactive Porphyrins Level — 33.0; 24.8; 19.7 Fluorescence intensity unit

Primary: Mean Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Improvement Compared to Placebo. — -6.2; -6.5; -6.2; -5.7 Scores on a scale — p=0.845

Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance

Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…

Primary: Investigator Global Assessment Scale for Severity of Facial Acne — 0; 0; 11; 9 Participants

Primary: CXCL10 in Skin — 273; 41; 7.5 Skin CXCL10 femtograms/micrograms — p=<0.01

Primary: Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment — 0.53 proportion of participants

Primary: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12 and 24 — -1.8; -0.5 score on a scale

Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…

Primary: Percentage of Participants With ≥75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75) — 76.0 percentage of participants

Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120

Primary: Percent Change in CD4+ T Effector Cells Expressing IL4 in Dupilumab-treated Subjects at Week 12 vs Week 0 — 68.4; 100.0 Percent change

Primary: Visual Analog Scale (VAS) — 3.35 units on a scale

Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieved Clear (0) or Almost Clear (1) on IGA Scale at Week 16 — 78 percentage of participants — p=<0.008

Primary: Change From Baseline in Cutaneous Dermatomyositis at 6 Months — -9 units on a scale — p=< .001

Primary: Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo — -1.8; -2.0; -0.6 wheal…

Primary: The Change in Number of Facial Inflammatory Acne-related Lesions. — 46; 23.7 Lesions

Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change

Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants

Primary: Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period — 29; 62 percentage of participants

Primary: Number of Participants Treated With Anakinra Who Achieve 50% Disease Improvement by the End of Week 12, as Measured by Total Body Surface Area Involvement (TBSAI50) — 7…